These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals

Vaxart (NASDAQ: VXRT) surged early in the coronavirus vaccine race. It climbed 2,400% in the first six months of 2020. That's as investors bet it would bring a potentially game-changing candidate to market. But Vaxart's program didn't move as quickly as those of vaccine market leaders Pfizer and Moderna. Vaxart's candidate currently is in a phase 2 study.

Data is expected in the first half of this year. But Vaxart has released reports from some preclinical studies that offer us reason to be optimistic. In fact, 19 words from Vaxart's chief scientific officer may mean big things for the biotech -- and trouble for vaccine rivals.

Image source: Getty Images.

Source Fool.com